Generex Ii-Key Technology for Development of COVID-19 Vaccine Featured in Media
Highlights Expertise of Dr. Eric von Hofe and Value of the NuGenerex Immune-Oncology Vaccine Platform
MIRAMAR, Fla., March 11, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB:GNBT), and its subsidiary, NuGenerex Immune-Oncology (NGIO), have been featured in several news outlets and on a podcast regarding its Ii-Key vaccine platform and its development of a COVID-19 (coronavirus) vaccine.
A Biocompare article titled “Coronavirus Vaccine Development Barrels Ahead” provides a Q&A with Dr. Eric von Hofe, NGIO Chief Scientific Officer, discussing the Ii-Key platform and its potential advantages:
A WIRED article titled "Everything You Need to Know About Coronavirus Vaccines” mentions Generex as a candidate developing a vaccine for the coronavirus:
In a Pharm Exec podcast, Dr. von Hofe discusses the coronavirus outbreak and vaccine candidates in development, including efforts by NGIO:
A South Florida Business Journal article titled “South Florida biotech secures funding to research coronavirus vaccine” discusses a contract with Beijing Zhonghua Investment Fund Management Co. for Generex’s Ii-Key technology:
A Genetic Engineering & Biotechnology News article titled “How to Conquer Coronavirus: Top 35 Treatments in Development” includes Generex:
A MedCity News article titled “Experts see cause for optimism in efforts to develop drugs, vaccines for coronavirus” interviews Dr. von Hofe about the benefits of the company’s technology for vaccine development:
The articles at the links above are provided for informational purposes only. Generex is not responsible for the content of the linked articles.
About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Generex Contact:
Generex Biotechnology Corporation
Joseph Moscato
646-599-6222
Todd Falls
1-800-391-6755 Extension 222
